1 / 35

Goals

Goals. Understand the differences between Hodgkin Lymphoma and non-Hodgkin Lymphoma Clinically and biologically Understand the differences between aggressive NHL and indolent NHL Clinically and biologically. C. Definition of Lymphoma. Heterogeneous group of lymphoproliferative malignancies

cai
Télécharger la présentation

Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Goals • Understand the differences between Hodgkin Lymphoma and non-Hodgkin Lymphoma • Clinically and biologically • Understand the differences between aggressive NHL and indolent NHL • Clinically and biologically

  2. C Definition of Lymphoma • Heterogeneous group of lymphoproliferative malignancies • Results from clonal expansion of tumor cells derived from B, T, or NK cells • 85%-90% in the US are derived from B cells • Variable clinical presentations • Range from asymptomatic pick up on routine blood work to painless adenopathy to an emergent medical problem • Pain, failure to thrive, organ failure • Characterized by variable natural histories and therapeutic responses

  3. Age at Diagnosis for Hodgkin’s andNon-Hodgkin’s Lymphoma ~56,390 NHL cases/y ~7,350 HD cases/y NHL Cases/100,000 Hodgkin’s Age at diagnosis (y) Data for diagnoses from 1997 to 2001. At: http://seer.cancer.gov. Accessed March 23, 2005.

  4. Non-Hodgkin’s Lymphoma:Epidemiology Estimated annualincidence ~4% compound annual increase in incidence Year Adapted from Greenlee et al. CA Cancer J Clin. 2001;51:15. Adapted from Jemal et al. CA Cancer J Clin. 2005;55:10.

  5. Hodgkin’s Disease

  6. Hodgkin Biology • RS is a “crippled” germinal center B cell • does not have normal B cell surface antigens • micromanipulation of single RS followed by PCR demonstrates clonally rearranged, but non functional immunoglobulin genes • somatic mutations result in stop codon (no sIg) • no apoptotic death malignant transformation • unclear how this occurs; ? EBV • unclear how cells end up with RS phenotype

  7. Hodgkin’s Disease • Clinical features • Often seen in young adults • Wide variety of presentations • B symptoms (fevers, night sweats, wt loss) • Pruritis • Cough/SOB • Pain • Painless adenopathy

  8. Hodgkin’s Disease • Approach to the Patient • staging evaluation • H & P • CBC, diff, plts • ESR, LDH, albumin, LFT’s, Cr • CT scans chest/abd/pelvis • bone marrow evaluation • PET scan in selected cases

  9. Ann Arbor Staging System for Hodgkin's Disease and Non-Hodgkin's Lymphoma Stage I Stage II Stage III Stage IV Reprinted with permission. Adapted from Skarin. Dana-Farber Cancer Institute Atlas of Diagnostic Oncology. 1991.

  10. Hodgkin’s Disease • Typical staging results • Most often disease is localized to above the diaphragm • Common to have extensive mediastinal disease • Tends to spread to contiguous nodal groups • Unlike NHL

  11. Approach to the Patient • Hodgkin’s Disease • approach dictated mainly by where the disease is located rather (results of staging) than the exact histologic subtype • NHL • approach is often dictated more by the histologic subtype than the results of staging

  12. Hodgkin Lymphoma: Treatment of limited stage disease

  13. Hodgkin Lymphoma: Prognostic Factors

  14. Hodgkins Disease Summary • B cell lymphoma • several histologic subtypes • Generally does not affect the approach to the patient • Reed-Sternberg Cells • Tends to occur in young adults • Mediastinal disease common • Spreads to contiguous nodes • Common to have a “localized” presentation • Highly curable with current treatments

  15. Non-Hodgkin’s Lymphoma • 30ish histologic subtypes • B cell (85%), T cell, NK cell • Histologic subtype dictates the approach to the patient • Median age at diagnosis 60 • Often widespread disease at diagnosis • Wide variation in outcome • Some cases rapidly fatal • Some cases readily curable • Some cases incurable but patient can live for many years with good quality of life

  16. WHO Classification:B-Cell Malignancies Harris NL et al. J Clin Oncol. 1999;17:3835-3849.

  17. WHO Classification:T-Cell Malignancies Harris NL et al. J Clin Oncol. 1999;17:3835-3849.

  18. Precursor cells Virgin (naïve) B cells Germinal-center and post–germinal-center B cells B-Cell Development Stem cell Immature B cell Follicle-center B cell s-IgM s-IgM/G/A CD79a CD22 CD79a TdT CD22 CD10 CD21 bcl6 CD21 HLA-DR HLA-DR CD20 CD34 HLA-DR CD20 CD19 CD19 Pre-pre–B cell Immunoblast s-IgM/G/A TdTc-CD22c-CD79a CD22 CD79a Mature B cell CD138± c-Ig s-IgM & IgD CD20 CD19 HLA-DR CD79a CD19 HLA-DR MUM1 CD22 CD21 HLA-DR Pre–B cell CD20 CD10 TdTc-CD22c-CD79ac-m CD19 Plasma cell CD20 CD79a CD138 c-Ig CD19 HLA-DR PCA-1 MUM1

  19. WM MM ALL MCL, CLL Burkitts, FL, DLBCL Stem cell Pre-B Early B Mature B Activated B Plasmacytoid B Plasma Germinal center • Type of B cell lymphoma is a function of: • Where the cell was in development/maturation when it went “bad” • What molecular derangement occurred Antigen Expression in B-Cell Lineage Jaffe. In: Non-Hodgkin’s Lymphoma. 1997:84.

  20. Models of Chromosomal Translocations in NHL REG REG REG REG CODING CODING CODING CODING Proto-oncogene Proto-oncogene TRANSLOCATION TRANSLOCATION REG REG COD ING CODING TRANSCRIPTIONALDEREGULATION FUSIONPROTEIN REG = regulatory sequence. Harris NL et al. Hematology (Am Soc Hematol Educ Program). 2001:194-220.

  21. Chromosomal Translocations Commonly Associated With Activation in B-Cell Malignancies National Comprehensive Cancer Network. Practice Guidelines in Oncology. v.1.2005.

  22. Lymphoma Biology • Aggressive NHL • short natural history (patients die within months if untreated) • disease of rapid cellular proliferation • Potentially curable with chemotherapy • Indolent NHL • long natural history (patients can live for many years untreated) • disease of slow cellular accumulation • Generally incurable with chemotherapy

  23. NHL: Presentation and Staging • Aggressive NHL • Patients likely to present with symptoms • Indolent NHL • Patients likely to present with painless adenopathy • Initial workup similar to Hodgkin Lymphoma

  24. NHL: Approach to the Patient • Approach dictated mainly by histology • reliable hematopathology crucial • Aggressive NHL • Cure is often the goal • Indolent NHL • Cure is rarely the goal • Control is the goal

  25. Most Common NHLs Armitage JO, Weisenburger DD. J Clin Oncol. 1998;16:2780-2795.

  26. Follicular Lymphoma

  27. Approach to Indolent NHL • Indolent NHL: guiding treatment principle • immediate treatment does not prolong overall survival for many patients • When to treat? • constitutional symptoms • compromise of a vital organ by compression or infiltration, particularly the bone marrow • bulky adenopathy • rapid progression • evidence of transformation • Will often begin with relatively non-toxic treatments and escalate the intensity of the therapy

  28. Diffuse Large B Cell Lymphoma

  29. Approach to Aggressive NHL • Patients have the potential to be cured • Administer most effective therapy (no matter how harsh) at diagnosis • If not cured, patients typically die within a few years of diagnosis

  30. International Prognostic Index for Age-Adjusted The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.

  31. DLBCL: Subtypes Revealed by Expression Array 1.0 Germinal-centerB-cell–like 0.8 0.6 Probability ActivatedB-cell–like 0.4 0.2 P = 7.9 E-6 0.0 0 2 4 6 8 10 Overall survival (years) Single histology with multiple molecular subtypes …with different outcomes Alizadeh AA et al. Nature. 2000;403:503-511.

  32. Summary • NHL incidence increasing • Hodgkin incidence stable or decreasing • Hodgkin Lymphoma • Characterized by the Reed-Sternberg Cells • Stage more important that histologic subtype • Often limited stage (stage I or II) • Spreads to contiguous nodes • Often affects younger patients • Very responsive to therapy • Cure rate quite high

  33. Summary • NHL cure rate mediocre • Many histologic subtypes • Often more important that the stage • indolent vs. aggressive • Function of underlying biology • indolent: • Often asymptomatic • Treatment: Less is more • aggressive: • Often symptomatic • require aggressive treatment ASAP to achieve cure

More Related